Malignancy of unknown origin

Synonym: cancers of unknown primary site

Most patients who have malignancy without an identifiable primary site have tumours derived from epithelial cells. Tumours derived from non-epithelial cells include melanoma, sarcoma, lymphoma and ovarian or testicular germ cell tumours.

Voir également le Carcinomatosis article.

Épidémiologie

In England and Wales about 4% of patients with newly diagnosed cancer are found to have cancer without an identifiable primary site, despite exhaustive tests.¹

• Most patients present with advanced-stage cancers and therefore usually have symptoms of malaise, weakness, fatigue and régime amaigrissant.

• Comprehensive history and physical examination are essential and should include breast, nodal areas, skin, genital, rectal and pelvic examination. Most patients present with areas affected in multiple visceral sites, especially lung, bone, lymph nodes and liver. Any investigations must be guided by reported symptoms and examination findings.

Investigations should only be performed if:¹

• The results are likely to affect a treatment decision.

• The patient understands why the investigations are being carried out.

• The patient understands the potential benefits and risks of investigation and treatment.

• The patient is prepared to accept treatment.

Enquêtes initiales¹

• Initial investigations should include FBC (iron deficiency may indicate an occult gastrointestinal malignancy), renal function tests and electrolytes, LFTs, calcium, lactate dehydrogenase and urinalysis (microscopic haematuria may indicate genitourinary malignancy).

• Radiographie thoracique.

• Myeloma screen (when there are isolated or multiple lytic bone lesions).

• Symptom-directed endoscopy.

• Computerised tomography (CT) scan of the chest, abdomen and pelvis.

• Prostate-specific antigen (PSA) in men.

• Cancer antigen 125 (CA 125) in women with peritoneal malignancy or ascites.

• Alpha-fetoprotein (AFP) and human chorionic gonadotrophin (hCG) (particularly in the presence of midline nodal disease).

• Testicular ultrasound in men with presentations compatible with germ cell tumours.

• Biopsy and standard histological examination, with immunohistochemistry where necessary, to distinguish carcinoma from other malignant diagnoses.

Specialised tests¹²

• Tumour markers should only be measured as follows:
  

  • AFP and hCG in presentations compatible with germ cell tumours (particularly mediastinal and/or retroperitoneal masses and in young men).

  • AFP in presentations compatible with hepatocellular cancer.

  • PSA in presentations compatible with prostate cancer.

  • CA 125 in presentations compatible with ovarian cancer (including inguinal node, chest, pleural, peritoneal or retroperitoneal presentations). Carefully interpret the results because of limited test specificity.

• Upper and lower gastrointestinal endoscopy: carry out only if the symptoms, histology or radiology suggest a gastrointestinal primary tumour.

• Mammography: do not offer routinely unless clinical or pathological features are compatible with breast cancer.

• Breast MRI scan: refer patients with adenocarcinoma involving the axillary nodes to a breast cancer specialist team. If a primary tumour is not identified after standard breast investigations, consider dynamic contrast-enhanced breast MRI to identify lesions suitable for targeted biopsy.

• 18F-fluorodeoxyglucose positron emission tomography-CT (18F-FDG PET-CT) scan:
  

  • Offer to patients with cervical lymphadenopathy if a primary tumour is not identified on ear, nose and throat panendoscopy and radical treatment is an option.

  • Consider for patients with extra-cervical presentations.

• Immunohistochemistry:
  

  • Use a panel of antibodies: cytokeratin 7, cytokeratin 20, thyroid transcription factor-1, placental alkaline phosphatase, oestrogen receptor (women only) and PSA (men only) in patients with adenocarcinoma of unknown origin.

  • If a primary tumour is not identified, use additional immunohistochemistry, guided by the results of the panel of antibodies and the clinical picture.

• Flexible bronchoscopy and video-assisted thoracoscopic surgery (VATS): when percutaneous biopsy is unsuitable or inappropriate for intrapulmonary nodules of probable metastatic origin, offer:
  

  • Flexible bronchoscopy with biopsy, brushings and washings, even when there is no endobronchial or central nodal disease on imaging.

  • Exploration with VATS - only after a negative bronchoscopic procedure.

• Histology to investigate malignant peritoneal disease: obtain a tissue sample for histology in patients with ascites, if technically possible.

• Gene-expression-based profiling should not be used to identify primary tumours.

An apparent metastasis may be an unusual primary tumour.¹

• All patients with possible malignancy of unknown primary origin should be referred immediately with a rapid referral pathway so that all patients are assessed within two weeks of referral.

• Patients should be referred to the specialist clinic for the specific tumour type if and when the primary malignancy is identified.

Service provision¹

• The National Institute for Health and Care Excellence (NICE) has recommended that every hospital with a cancer centre or unit should establish a carcinoma of unknown primary (CUP) team, and ensure that patients have access to the team when malignancy of undefined primary origin (MUPO) is diagnosed.

• The team should consist of an oncologist, a palliative-care physician and a CUP specialist nurse or key worker as a minimum and should have a named lead clinician.

Radical treatment

Presentations that may benefit from radical treatment:

• Upper- or mid-neck squamous cell carcinoma: refer to a head and neck multidisciplinary team.

• Adenocarcinoma involving the axillary nodes: refer to a breast cancer multidisciplinary team.

• Squamous cell carcinoma confined to the inguinal nodes: refer to a specialist surgeon in an appropriate multidisciplinary team to consider curative treatment. If the disease is operable, offer:
  

  • Superficial lymphadenectomy and consider post-lymphadenectomy radiotherapy (if there are risk factors for residual disease - eg, multiple involved nodes or extracapsular spread); or

  • Simple excision of clinically involved nodes, followed by radiotherapy.

• Solitary metastasis in the liver, brain, bone, skin or lung: refer to the appropriate multidisciplinary team to consider radical local treatment.

Chemotherapy for confirmed CUP origin

• Offer chemotherapy directed at a specific treatable syndrome if patients have clinical and/or laboratory features of a specific treatable syndrome and adequate performance status.

• If patients do not have clinical features of a specific treatable syndrome, tell them about the potential benefits and risks of chemotherapy.

• Offer patients the opportunity to enter clinical trials. If chemotherapy is offered outside clinical trials, when deciding which treatment to use, take into account the clinical and pathological characteristics of the tumour and the toxicity profile of the drugs, their ease of administration and response rate.

Multiple metastases including brain involvement¹

• After initial and special investigations, refer patients with apparent brain metastases as the only sign of malignant disease to a neuro-oncology multidisciplinary team.

• Do not offer chemotherapy except as part of a controlled clinical trial.

• Inform patients and carers that there is no evidence that any treatment offers improved survival and there is limited evidence that surgery and/or whole brain radiotherapy improves neurological symptoms.

Soins palliatifs

Voir l'article séparé Soins palliatifs, Soins de fin de vie, Looking After People With Cancer, Helping Patients Face Death and Dying, Prescription en soins palliatifs, Gestion de la douleur en soins palliatifs et Nausea and Vomiting in Palliative Care articles.

Malignancies of unknown primary origin are by definition metastatic cancers and the prognosis is generally poor. However, an appropriate diagnostic work-up can help to identify a minority of patients who can expect to benefit from directed therapy.²